Pharmafile Logo
Pharmafocus logo
Advanced Search

Lyxumia

Showing 6 posts of 6 posts found.

sanofi_hq__boetie_hall

Sanofi gets FDA approval for type-2 diabetes treatment Adlyxin

July 28, 2016
Research and Development, Sales and Marketing FDA, Lixisenatide, Lyxumia, Sanofi, adlyxin, approval, diabetes, type 2, type-2, zealand

Sanofi has announced that the US Food and Drug Administration (FDA) has approved Adlyxin (lixisenatide), which is a once-daily mealtime …

News
Victoza

Novo Nordisk looks to HEOR data to back Victoza

November 11, 2015
Research and Development, Sales and Marketing Byetta, HEOR, Lyxumia, NHS, Novo Nordisk, Victoza, cost-effectiveness

A Novo Nordisk-sponsored study of the cost-effectiveness of three different injectable anti-diabetes drugs has found Victoza is a cheaper option …

News
Sanofi image

Sanofi diabetes drug fails to show cardio disease benefit

March 19, 2015
Research and Development, Sales and Marketing ACS, Lixisenatide, Lyxumia, Sanofi, cardio, diabetes

A Phase IIIb study of Sanofi’s diabetes drug lixisenatide has shown it is no better or worse than a placebo …

News
sanofi image

Sanofi escapes most serious censure

December 13, 2013
Medical Communications, Sales and Marketing ABPI, Lyxumia, PMCPA, Sanofi, censure

Sanofi has been cleared of the most serious breach of the ABPI Code of Practice – despite appearing to offer …

News

Sanofi celebrates EU approvals

February 5, 2013
Sales and Marketing Lyxumia, Sanofi, Zaltrap, diabetes

Sanofi is celebrating after diabetes treatment Lyxumia (lixisenatide) and metastatic colorectal cancer (mCRC) drug Zaltrap received authorisation in Europe. The …

News
sanofi website

Positive data for Sanofi’s diabetes drug

June 13, 2012
Research and Development, Sales and Marketing Lyxumia, Novo Nordisk, Sanofi, Victoza, diabetes

Sanofi’s new diabetes treatment Lyxumia has significantly reduced glycated hemoglobin (HbA1c) in two late-stage trials, the manufacturer says. Paris-based Sanofi …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025